Merck wins FDA label expansion for Welireg in neuroendocrine tumors

JHVEPhoto

The U.S. Food and Drug Administration (FDA) on Wednesday approved Merck’s (NYSE:MRK) anti-cancer agent Welireg (belzutifan) as a treatment for rare neuroendocrine tumors, pheochromocytoma, or paraganglioma.

Accordingly, the oral therapy will be indicated for those aged 12 and older with locally